Inhibition of intestinal .ALPHA.-glucosidase and postprandial hyperglycemia by N-substituted moranoline derivatives.
- 1 January 1988
- journal article
- research article
- Published by Pharmaceutical Society of Japan in Journal of Pharmacobio-Dynamics
- Vol. 11 (5) , 356-362
- https://doi.org/10.1248/bpb1978.11.356
Abstract
The inhibitory activity of N-substituted derivatives of moranoline (1-deoxynojirimycin) against intestinal .alpha.-glucosidase and postprandial hyperglycemia was evaluated. None of the N-substituted derivatives studied displayed more potent inhibition of sucrase or maltase from rabbit intestines than the parent compound moranoline. However, unlike the in vitro results, many compounds exhibited more potent hypoglycemic activities than moranoline in sucrose-, or starch-loaded rat models. Alkenyl or aralkenyl derivatives displayed more potent hypoglycemic activities than alkyl or aralkyl derivatives. There was a weak correlation between in vitro and in vivo assay systems found by statistical analysis. It is necessary to evaluate compounds in vivo in order to select the most potent hypoglycemic compound.This publication has 5 references indexed in Scilit:
- A DOUBLE-BLIND-STUDY ON THE EFFICACY AND TOLERANCE OF A NEW ALPHA-GLUCOSIDASE INHIBITOR IN TYPE-2 DIABETICS1986
- Effects of the?-glucosidase inhibitor 1 desoxynojirimycin (BAY M 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patientsEuropean Journal of Clinical Pharmacology, 1986
- Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabeticsEuropean Journal of Clinical Pharmacology, 1986
- Moranoline (1-Deoxynojirimycin) Fermentation and Its ImprovementAgricultural and Biological Chemistry, 1985
- The effect of a 1-deoxynojirimycin derivative on post-prandial blood glucose and insulin levels in healthy black and white volunteersEuropean Journal of Clinical Pharmacology, 1985